Aligos Therapeutics’ (ALGS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $50.00 price target on the stock.

ALGS has been the topic of a number of other research reports. UBS Group started coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $35.00.

Aligos Therapeutics Stock Performance

NASDAQ:ALGS opened at $7.57 on Wednesday. The company has a market capitalization of $46.59 million, a price-to-earnings ratio of -0.88 and a beta of 2.67. Aligos Therapeutics has a one year low of $3.76 and a one year high of $13.69. The stock has a 50-day simple moving average of $7.75 and a 200 day simple moving average of $9.02.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.09) by $0.18. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. On average, equities research analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALGS. Woodline Partners LP purchased a new position in Aligos Therapeutics during the 1st quarter worth approximately $2,602,000. Marshall Wace LLP purchased a new position in Aligos Therapeutics during the 4th quarter valued at about $2,504,000. Sio Capital Management LLC lifted its position in shares of Aligos Therapeutics by 85.9% in the second quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after purchasing an additional 155,217 shares in the last quarter. SummitTX Capital L.P. acquired a new stake in shares of Aligos Therapeutics during the fourth quarter worth approximately $1,299,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Aligos Therapeutics during the fourth quarter worth approximately $664,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.